Compare Broadcom Inc (AVGO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Broadcom Inc vs Mesoblast Limited — how do they compare? Broadcom Inc trades at $424.19 (market cap $1.98T), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Broadcom Inc is far larger — about 895.9× Mesoblast Limited's market cap, and Broadcom Inc pays a 0.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| AVGO | MESO | |
|---|---|---|
Market Cap | $1.98T | $2.21B |
Sector | Technology | Technology |
52-Week High | $481.57 | $20.96 |
52-Week Low | $289.60 | $12.88 |
Enterprise Value | $2.02T | $2.21B |
Dividend Yield | 0.62% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
